Program

ENTIS board meeeting

ENTIS board meeting with committees, 15 min. each: Website, Membership, Organization

Working Lunch

OTIS/ENTIS collaborative meeting 

Working Lunch

ENTIS business meeting

Download agenda (.pdf)

ENTIS business meeting cont. including short presentation by new TIS 

Celebrating 30 years of TIS

Christof Schaefer, TIS Berlin (Germany) 

Session 1 Malformations

Chair: Laura Yates

Welcome

President of ENTIS, Laura Yates (UK), and head of Organizing Committe, Hedvig Nordeng (Norway)

Dysmorphological investigation of children in practice

Miguel Del Campo, Rady Children's Hospital-San Diego. UC San Diego. Center for Better Beginnings. (USA)

Clinical cases

Miguel Del Campo, Rady Children's Hospital-San Diego. UC San Diego. Center for Better Beginnings. (USA)
Matteo Cassina, Clinical Genetics Unit, Department of Women's and Children's health, University of Padova (Italy)

Session 2 Medications in Pregnancy

Chair: Corinna Weber-Schoendorfer

Pharmacokinetics in Pregnancy

Prof. Olav Spigset, Department of Clinical Pharmacology, St. Olavs Hospital, Trondheim University Hospital (Norway)

Monitoring serum concentrations of antiepileptics in pregnancy - to do or not to do?

Cecilie Johannessen Landmark, Faculty of Health Sciences, OsloMet - Oslo Metropolitan University. National Centre for Epilepsy and Department of Pharmacology, Oslo University Hospital (Norway)

What do you know about recent teratology studies? Test yourself

Corinna Weber-Schoendorfer, TIS Berlin (Germany)

Session 3 Free Communications!

Chair: Herbert Juch

Pregnancy outcome following 1st trimester exposure to fingolimod: preliminary results of a collaborative ENTIS study –

Emmanuelle Pauliat, STIS and Clinical Pharmacology Service, CHUV, Lausanne, Switzerland

Can folic acid reduce risk of pregnancy complications in women with epilepsy?

Silje Alvestad , University of Bergen, Norway

Use of macrolide antibiotics during pregnancy and risk of major congenital malformations and heart defects: Preliminary results of a systematic review and meta-analysis

Elif Keskin-Arslan, Department of Pharmacology, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey

Maternal ondansetron use and the risk of congenital malformations; an updated meta-analysis

- Jonathan Luke Richardson^, UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust,     Newcastle-upon-Tyne, United Kingdom

Session 4 Social events

Session 5 Medications and Breast feeding

Chair: Hedvig Nordeng

Key note: Biorepository of breast milk and breast milk studies – an overview of activities at the Center for Better Beginnings

Christina Chambers, University of California, San Diego School of Medicine. Center for Better Beginnings. President OTIS (USA)

Key note: Medial conditions complicating breastfeeding

Solveig Thorp Holmsen, National Resources Center for Breastfeeding (Norway)

Session 6 Medication in breastmilk and Free Communications!

Chair: Orna Diav-Citrin

Key note: Analysing medications in breast milk – from case reports to modelling

Alice Panchaud, TIS Lausanne (Switzerland)

Free C: Levetiracetam monitoring in breast milk

Natalie Dinavitser, Clinical Pharmacology and Toxicology Unit, Drug Consultation Center, Assaf Harofeh Medical Center, Zerifin, Affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Free C: Safety of statins in the first trimester of pregnancy: an updated meta-analysis

Thierry Vial, Department of Pharmacotoxicology, University hospital of Lyon, France

Free C: Why does renin-angiotensin system inhibitor system inhibitor exposure happen during later pregnancy despite warnings - an approach to the problem

Corinna Weber-Schoendorfer, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany

Free C: Online data acquisition using REDCap - Long-term follow-up of children with intrauterine drug exposure

Evelin Beck, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany

Session 7 Hot topic and poster pitches

Chair: Per Damkier

15 min + 15 min debate "Paracetamol and ductus arteriosus"

Karel Allegaert, KU Leuven, author of the paper "Maternal paracetamol intake and fetal ductus arteriosus constriction or closure: a case series analysis" will present his views. Prof. Per Damkier, The University of Southern Denmark, will debate the topic.

Session 8 Methods

Chair: Cem Kaplan

Key note: Spontaneous ADR reports - How can they be used to detect teratogens?

Eugene van Puijenbroek, Netherlands Pharmacovigilance Center Lareb (The Netherlands)

Key note: New and advanced methods of meta-analysis - meta-regression, network meta-analysis and trial sequential analysis

Ilan Matok, Institute for Drug Research, School of Pharmacy, Jerusalem (Israel)

Pharmacovigilance of medication safety in pregnancy - a European regulatory prespective

Dr. Ulla Wändel Liminga, Medical Products Agency, Sweden